Pharmacovigilance and Safety Assessment

Pharmacovigilance and safety assessment are critical components of drug development and post-market surveillance, ensuring the safety and efficacy of pharmaceutical products. Pharmacovigilance involves the monitoring, detection, assessment, and prevention of adverse drug reactions (ADRs) or other drug-related problems. Safety assessments include preclinical and clinical trials, where potential risks are evaluated in controlled environments, followed by real-world monitoring once the drug is marketed. This ongoing process helps identify rare or long-term side effects and ensures that the benefits of a drug continue to outweigh the risks. Effective pharmacovigilance promotes public health and regulatory compliance, supporting patient safety across diverse therapeutic areas.

 

    Related Conference of Pharmacovigilance and Safety Assessment

    April 16-17, 2025

    9th International Conference on Internal Medicine

    Berlin, Germany
    May 12-13, 2025

    19th International Conference on Obesity Medicine

    Toronto, Canada
    June 24-25, 2025

    3rd Global Summit on HIV-AIDS and STDs

    Chicago, USA
    July 21-22, 2025

    24th International Conference on Genomics and Molecular Biology

    Aix-en-Provence, France
    July 21-22, 2025

    11th World Congress on Anesthesia and Critical Care

    Aix-en-Provence, France
    August 07-08, 2025

    12th World Summit on Epilepsy and Bipolar Disorders

    Paris, France
    October 16-17, 2025

    19th International Conference on Pathology and Laboratory Medicine

    Aix-en-Provence, France
    November 03-04, 2025

    5th World Medicine Congress

    Rome, Italy

    Pharmacovigilance and Safety Assessment Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in